安罗替尼联合多西他赛对比单药多西他赛在驱动基因阴性晚期非小细胞肺癌二线治疗的临床研究  

Clinical Study of Anrotinib Combined with Docetaxel Versus Single-agent Docetaxel in the Second-line Treatment of Driver-Negative Advanced Non-small Cell Lung Cancer

作　　者：肖集文[1] XIAO Ji-wen(Huaihua First People's Hospital,Huaihua Hunan 418000,China)

机构地区：[1]怀化市第一人民医院,湖南怀化418000

出　　处：《药品评价》2020年第6期49-50,53,共3页Drug Evaluation

摘　　要：目的:探讨安罗替尼联合多西他赛治疗驱动基因阴性晚期非小细胞肺癌(NSCLC)的临床疗效。方法:选取我院驱动基因阴性晚期NSCLC患者78例(2018年6月至2019年1月),采用随机数字表法分为联合组(n=39)、单一组(n=39)。单一组采用单药多西他赛治疗,联合组采用安罗替尼联合多西他赛治疗,统计比较两组临床疗效、不良反应发生率及治疗前后生存质量量表(WHOQOL-BREF)、卡氏(KPS)评分、中位生存期。结果:联合组疾病控制率(DCR)76.92%高于单一组53.85%(P<0.05);联合组恶心呕吐发生率5.13%、腹泻发生率5.13%低于单一组20.51%、23.08%(P<0.05);治疗4个周期后联合组WHOQOL-BREF、KPS评分高于单一组(P<0.05);联合组中位生存期长于单一组(P<0.05)。结论:安罗替尼联合多西他赛治疗驱动基因阴性晚期NSCLC患者疾病控制情况优于单药多西他赛,可降低不良反应发生率,改善患者生存质量,且远期疗效好。Objective:To investigate the clinical efficacy of enrotenib combined with docetaxel in the treatment of driver gene negative advanced non-small cell lung cancer(NSCLC).Methods:A total of 78 patients(from June 2018 to January 2019)with negative driver gene in advanced NSCLC in our hospital were selected and randomly divided into a combined group(n=39)and a single group(n=39).The single group was treated with single-drug docetaxel,and the combined group was treated with anrotinib combined with docetaxel.The clinical efficacy,incidence of adverse reactions,quality of life scale(WHOQOL-BREF),KPS score,and median survival were statistically compared between the two groups.Results:DCR 76.92% in the combined group was higher than 53.85% in the single group(P<0.05).The incidence of nausea and vomiting in the combined group was 5.13%,and the incidence of diarrhea was 5.13% lower than that in the single group(20.51%,23.08%,P<0.05).The WHOQOLBREF and KPS scores of the combined group were higher than those of the single group after 4 cycles of treatment(P<0.05).The median survival time of the combined group was longer than that of the single group(P<0.05).Conclusion:The disease control of patients with negative driver genes in advanced NSCLC treated with enrotenib combined with docetaxel is better than that of single drug docetaxel,which can reduce the incidence of adverse reactions and improve the quality of life of patients with good long-term efficacy.

关 键 词：驱动基因阴性 晚期非小细胞肺癌 多西他赛 安罗替尼 中位生存期 

分 类 号：R979.1[医药卫生—药品]